Medivation (MDVN) PT Raised to $70 at RBC Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Needham & Company Sees Little Upside in Medivation (MDVN)
May 9, 2016 3:57 PM EDTNeedham & Company analyst Chad Messer weighed in on Hold-rated Medivation (NASDAQ: MDVN), saying another Xtandi miss is being overlooked by the takeover battle. The analyst sees little upside from current levels.
Messer commented, "Medivation rejected Sanofi's recent $52.50/share ($9.3 billion) takeover bid. However,... More
Medivation (MDVN) PT Raised to $50 at BMO Capital
May 6, 2016 9:12 AM EDTBMO Capital analyst Do Kim raised his price target on Medivation (NASDAQ: MDVN) to $50.00 (from $47.00) but maintained a Market Perform rating.
Kim commented, "Medivation provided the most transparency ever on its pipeline and revenue expectations in response to Sanofis unsolicited offer of... More
Medivation (MDVN) PT Raised to $56 at Jefferies
May 6, 2016 7:52 AM EDTJefferies analyst Biren Amin bumped his price target on Medivation (NASDAQ: MDVN) to $56.00 (from $52.00) but maintained a Hold rating.
Amin commented, "MDVN reported $307.6M in U.S. Xtandi sales despite seasonal headwinds and reiterated sales guidance of $1.425-1.525B in 2016 and issued long term... More
Citi Upgrades Medivation (MDVN) to Buy
May 6, 2016 7:39 AM EDTCiti upgraded Medivation (NASDAQ: MDVN) from Neutral to Buy.
For an analyst ratings summary and ratings history on Medivation click here. For more ratings news on Medivation click here.
Shares of Medivation closed at $59.22 yesterday.
... MoreMedivation (MDVN) Is All About Price Now - Leerink
May 6, 2016 7:09 AM EDTLeerink Partners analyst, Geoffrey Porges, raised his PT on Medivation (NASDAQ: MDVN) to the takeout price: $64 from $39. No change to Market Perform rating.
Medivation presented its keenly awaited Q1 financial results, and then delivered an extended explanation of managements view of the companys many value drivers, and of the basis for its summary rejection of Sanofis (OP) unsolicited written offer (and of their... More
Medivation (MDVN) Misses Q1 EPS by 12c, Sales Miss; Reaffirms
May 5, 2016 4:15 PM EDTMedivation (NASDAQ: MDVN) reported Q1 EPS of $0.11, $0.12 worse than the analyst estimate of $0.23. Revenue for the quarter came in at $182.5 million versus the consensus estimate of $196.61 million.
"Medivation is off to a strong start in 2016 as we continue to expand our leadership position in oncology, extend XTANDI's reach into urology and other areas, and advance our robust late-stage pipeline," said David Hung, M.D., Founder, President and Chief Executive Officer of Medivation. "The... More
